Chemotherapy of hematological malignancies in patients with COVID-19

In the era of COVID-19, the chemotherapy of patients with hematological malignancies has become the cornerstone in hematology. Secondary immunodeficiency as a result of hemoblastosis, predisposes to a more severe course of coronavirus infection, and specific antitumor treatment only exacerbates patients immunodeficiency. Thus, there is a problem of conducting chemotherapy during the COVID-19 pandemic. At the moment, there are no unified recommendations for risk assessment and choice of treatment for patients with oncohematological diseases and concomitant coronavirus infection. In this article, we present a series of clinical cases of patients with hematological malignancies diagnosed with coronavirus infection at the onset of a hematological disease or after chemotherapy. Patients with long-term persistent coronavirus infection requiring specific anticancer treatment were allocated to a separate group. We hope that this article will help to set a vector for further research, as well as serve as a clear example of the clinical situations that a hematologist may face during the COVID-19 pandemic.

1. Na I.K., Buckland M., Agostini C. et al. Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies. Eur J Haematol 2019;102(6):447–56. DOI:10.1111/ejh.13223.

2. Ye C., Liu J., Song X. et al. A clinician survey for management of the secondary immunodeficiency caused by hematological malignancies in China. Medicine 2021;100(3):e23935. DOI:10.1097/MD.0000000000023935.

3. García-Suárez J., de la Cruz J., Cedillo Á. et al. Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study. J Hematol Oncol 2020;13(1):133. DOI:10.1186/s13045-020-00970-7.

4. Vijenthira A., Gong I.Y., Fox T.A. et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood 2020;136(25):2881–92. DOI:10.1182/blood.2020008824.

5. Cattaneo C., Daffini R., Pagani C. et al. Clinical characteristics and risk factors for mortality in hematologic patients affected by COVID-19. Cancer 2020;126(23): 5069–76. DOI:10.1002/cncr.33160.

6. Fox T.A., Troy-Barnes E., Kirkwood A.A. et al. Clinical outcomes and risk factors for severe COVID-19 in patients with haematological disorders receiving chemo- or immunotherapy. Br J Haematol 2020;191(2):194–206. DOI:10.1111/bjh.17027.

7. Liu H., Yang D., Chen X. et al. The effect of anticancer treatment on cancer patients with COVID-19: a systematic review and meta-analysis. Cancer Med 2021;10(3):1043–56. DOI:10.1002/cam4.3692.

8. Passamonti F., Cattaneo C., Arcaini L. et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol 2020;7(10):e737–45. DOI:10.1016/S2352-3026(20)30251-9.

9. Острый промиелоцитарный лейкоз. Национальные клинические рекомендации 2020. C. 33–34.

10. Grever M., Andritsos L., Banerji V. et al. Hairy cell leukemia and COVID-19 adaptation of treatment guidelines. Leukemia 2021;35(7):1864–72. DOI:10.1038/s41375-021-01257-7.